<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144608</url>
  </required_header>
  <id_info>
    <org_study_id>TOGATHER</org_study_id>
    <nct_id>NCT04144608</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yongchang Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to investigate the safety and efficacy of Toripalimab Combined With
      Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation
      Non-small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 surgical resection rate</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>No residual ratio under the microscope after surgical resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>To measure the patients's overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>Neoadjuvant therapy-induced tumor regression in pathologically residual tumors &lt;10%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Toripalimab Combined With Platinum-containing Dual-agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treprilumab combination with platinum-containing dual-drug chemotherapy</intervention_name>
    <description>Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1</description>
    <arm_group_label>Toripalimab Combined With Platinum-containing Dual-agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously untreated, histologically confirmed potentially resectable stage IIIA or
             IIIB (AJCC staging eighth edition) NSCLC; potentially resectable refers to a
             discussion by the surgeon, including primary T3 or T4, mediastinum Lymph node
             metastasis (N2) is defined as: single-site or multi-station metastasis can be
             confirmed by imaging or pathology with a short diameter â‰¥ 2 cm, and it is expected
             that resection is difficult or pneumonectomy is required;

          2. Before the enrollment, submit the PD-L1 immunohistochemistry section and the
             corresponding pathology report for biomarker evaluation (the tumor tissue sample must
             be fresh or archived samples obtained within 3 months before enrollment; Fresh tissue
             must be a needle biopsy, excision or incision biopsy specimen);

        Exclusion Criteria:

        Patients received Toripalimab before Patients with contraindication of chemotherapy
        Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Z MD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Province Tumor Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang Z MD, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Provincal Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762327</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Nong Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongchang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Toripalimab NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

